UpdatesPress Release
Akums reported strong Q1 FY27 results.
Akums Drugs and Pharmaceuticals LimitedAKUMS · Filed with the exchange
Revenue surged 13.9% YoY to ₹1,167 Cr, EBITDA grew 35.4% to ₹175 Cr, and PAT hit ₹101 Cr.
CDMO business was the key driver, fueled by volume growth.
No comments yet. Be the first.